Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Suven Life Sciences has started the Phase I clinical trials of SUVN-502, a potent, safe, highly selective, brain penetrant and orally active antagonist at a nonperipheral CNS receptor site 5-HT6, intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like attention deficient hyperactivity, Parkinson, schizophrenia.
Subscribe to our email newsletter
The Phase I study is being conducted using single and multiple oral doses with the objective of assessing safety and bioavailability of SUVN-502 in 67 healthy human beings. The study is being conducted at Basel, Switzerland under a clinical trial application approved by SwissMedic, the regulatory authority of Switzerland.
The single ascending dose studies are expected to be complete by September 2008 and multiple ascending dose studies are to be conducted during October-December 2008.
Suven is also in discussions for potential licensing partners for this compound. Timing of the licensing would depend on the deal terms and ability to get co-promotion rights in some of the targeted markets. The company targets to launch this molecule in 2012.